| Autor: |
Lakehal F; Department of Pharmaceutics, University of Washington, Seattle, WA 98195-7610, USA., Wurden CJ, Kalhorn TF, Levy RH |
| Jazyk: |
angličtina |
| Zdroj: |
Epilepsy research [Epilepsy Res] 2002 Dec; Vol. 52 (2), pp. 79-83. |
| DOI: |
10.1016/s0920-1211(02)00188-2 |
| Abstrakt: |
Multiple studies suggest that phenytoin concentrations increase with CBZ co-medication. This study evaluated the hypothesis that CBZ and/or its major metabolite (CBZE) inhibit CYP2C19-mediated phenytoin metabolism using human liver microsomes and cDNA-expressed CYP2C19. Oxcarbazepine (OXC), and its 10-monohydroxy metabolite (MHD) were also evaluated. CBZ and MHD inhibited CYP2C19-mediated phenytoin metabolism at therapeutic concentrations. Thus, administration of CBZ and OXC with CYP2C19 substrates with narrow therapeutic ranges should be done cautiously. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect